Skip to main content

Table 2 MOS-sleep and EQ-5D questionnaire scores by treatment group

From: Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

 

Pregabalin

Usual care

p between groups

N= 486

N= 239

Baseline

Final

Change (95% CI)

Baseline

Final

Change (95% CI)

Baseline

Final a

MOS-sleep scale, mean (SD)

        

  Sleep disturbance (0–100)

58.1 (18.9)

27.1 (17.5)

−29.3 (−31.1, −27.4)**

50.1 (20.7)

32.0 (21.2)

−22.4 (−24.9, −19.9)**

<0.001

<0.001

  Snoring while sleep (0–100)

32.5 (29.0)

23.9 (26.0)

−7.1 (−9.0, −5.2)**

30.2 (30.3)

24.7 (26.9)

−4.8 (−7.4, −2.2)**

0.175

0.142

  Awakening short of breath (0–100)

39.9 (22.8)

17.7 (19.6)

−20.3 (−22.2, −18.4)**

30.6 (23.9)

20.9 (22.9)

−13.2 (−15.7, −10.6)**

<0.001

<0.001

  Optimal sleep (0–1)

0.19 (0.39)

0.65 (0.48)

0.46 (0.41, 0.51)**

0.26 (0.44)

0.61 (0.49)

0.41 (0.34, 0.48)**

<0.050

0.268

  Sleep quality (0–100)

28.3 (19.7)

61.3 (24.0)

31.1 (28.7, 33.5)**

35.7 (22.6)

55.1 (26.1)

22.8 (19.5, 26.1)**

<0.001

<0.001

  Daytime sleepiness (0–100)

38.6 (18.6)

21.6 (15.9)

−16.0 (−17.6, −14.4)**

33.7 (19.3)

23.6 (18.5)

−12.5 (−14.6, −10.3)**

<0.001

0.006

  Sleep hours per night (0–24)

5.53 (1.25)

6.91 (1.05)

1.27 (1.16, 1.38)**

5.95 (1.53)

6.91 (1.13)

1.14 (0.98, 1.31)**

<0.001

0.170

  General index sleep problems (0–100)

55.0 (15.0)

27.0 (16.0)

−26.4 (−28.1, −24.7)**

47.5 (16.8)

31.2 (19.1)

−19.6 (−22.0, −17.3)**

<0.001

<0.001

EQ-5D questionnaireb

        

  Mobility

1.40 (0.50)

1.22 (0.44)

−0.17 (−0.21, −0.13)*

1.29 (0.50)

1.17 (0.39)

−0.17 (−0.22, −0.12)*

0.002

0.922

[39.4]

[21.4]

 

[27.1]

[17.0]

 

<0.001

0.375

  Personal care

1.26 (0.45)

1.09 (0.29)

−0.15 (−0.18, −0.12)*

1.19 (0.42)

1.12 (0.36)

−0.12 (−0.16, −0.08)*

0.027

0.174

[26.0]

[8.7]

 

[18.4]

[10.3]

 

0.032

0.196

  Activities of daily living

2.14 (0.50)

1.56 (0.54)

−0.52 (−0.58, −0.47)**

1.88 (0.49)

1.59 (0.58)

−0.43 (−0.51, −0.36)**

<0.001

0.047

[93.3]

[53.3]

 

[81.5]

[54.7]

 

<0.001

0.221

  Pain/discomfort

2.11 (0.63)

1.57 (0.60)

−0.51 (−0.56, −0.45)**

1.90 (0.63)

1.58 (0.62)

−0.42 (−0.49, −0.35)**

<0.001

0.043

[85.4]

[51.5]

 

[74.6]

[50.8]

 

<0.001

0.789

  Anxiety/depression

2.52 (0.52)

1.54 (0.58)

−0.94 (−1.00, −0.64)**

2.37 (0.57)

1.75 (0.61)

−0.72 (−0.80, −0.64)**

0.001

<0.001

[98.8]

[50.0]

 

[95.8]

[65.7]

 

0.002

<0.001

Self-valuation quality of life (EQ-VAS; 0–100)

42.7 (15.5)

70.0 (17.3)

26.4 (24.7, 28.1)**

48.9 (15.7)

65.5 (18.3)

19.4 (17.1, 21.6)**

<0.001

<0.001

Health status (utility index; 0–1)

0.40 (0.30)

0.78 (0.25)

0.36 (0.34, 0.38)**

0.53 (0.31)

0.75 (0.28)

0.29 (0.26, 0.33)**

<0.001

<0.001

  1. Values are expressed as mean (SD, standard deviation) or 95% confidence intervals (CI) unless otherwise stated.
  2. aComparison of the change from baseline between the two groups adjusted by baseline values and sex and age.
  3. bThe percentage of patients who still have problems (sum of categories 2 and 3) for each EQ-5D component are expressed within brackets.
  4. p < 0.05, *p < 0.01, **p < 0.001 vs. baseline values.